Rezolute's Ersodetug Advances in Phase 3 Trials for Hyperinsulinism
核心洞察
Rezolute is advancing ersodetug, a monoclonal antibody, in two Phase 3 trials for congenital and tumor hyperinsulinism (搜索) (HI).
The sunRIZE study for congenital HI (搜索) is enrolling patients outside the U.S., with U.S. enrollment expected to begin in early 2025.
A Phase 3 study for tumor HI (搜索) is anticipated to commence in the first half of 2025, building on the success of the Expanded Access Program.
Rezolute, Inc. is focusing on the execution of its two Phase 3 programs evaluating ersodetug for congenital and tumor hyperinsulinism (搜索) (HI). Ersodetug, a fully human monoclonal antibody, is designed to improve hypoglycemia (搜索) by counteracting the effects of insulin receptor over-activation.
sunRIZE Trial for Congenital HI
The sunRIZE study, a global, pivotal Phase 3 clinical trial, is currently enrolling patients outside the U.S. to assess the efficacy and safety of ersodetug in congenital HI (搜索) patients with poorly controlled hypoglycemia (搜索). Enrollment of U.S. participants is expected to begin in early 2025. The study includes participants aged 3 months to 45 years and aims to enroll up to 56 participants across multiple countries. Topline results from the sunRIZE trial are anticipated in the second half of 2025.
Phase 3 Trial for Tumor HI
Rezolute is also progressing with start-up activities for a Phase 3 registrational study of ersodetug in patients with tumor HI (搜索). Patient enrollment is projected to commence in the first half of 2025, with topline results expected in the second half of 2026. This trial builds upon the success observed in the Expanded Access Program, indicating the potential of ersodetug in treating tumor-induced HI.
Financial Update
As of September 30, 2024, Rezolute reported cash, cash equivalents, and investments in marketable securities totaling $117.8 million. Research and development expenses for the first quarter of fiscal year 2025 were $12.8 million, compared to $12.2 million for the same period last year. The increase is primarily attributed to increased expenditures in clinical trial activities, manufacturing costs, and personnel-related expenses. General and administrative expenses were $4.2 million for the first quarter of fiscal 2025, compared with $3.7 million for the same period a year ago, with the increase primarily attributable to professional fees and employee-related expenses as a result of increased headcount. The net loss for the first quarter of fiscal 2025 was $15.4 million, compared to a net loss of $14.5 million for the same period a year ago.
About Ersodetug's Mechanism
Ersodetug binds to a unique allosteric site on insulin receptors, counteracting the effects of insulin receptor over-activation by insulin and related substances like IGF-2. This mechanism has the potential to be universally effective in treating hypoglycemia (搜索) due to any form of HI, as it acts downstream from the pancreas.